Article
An updated review of the treatment landscape for advanced gastrointestinal stromal tumors.
Cancer - 1 Jul 2021
Patel Shreyaskumar R, Reichardt Peter
Abstract excerpt
Before the introduction of tyrosine kinase inhibitors (TKIs), the overall survival of patients with advanced or metastatic gastrointestinal stromal tumors (GISTs) was 10 to 20 months because of the lack of approved therapies. In the last 20 years, a treatment algorithm for patients with advanced GISTs, which includes imatinib, sunitinib, and regorafenib as first-, second-, and third-line therapies, respectively,...
Topics
Join the communities discussing this publication.